HarMono-T microbubble - Solstice Pharmaceuticals
Alternative Names: HarMono-T Contrast Agent; Lipid-coated gas-filled microbubblesLatest Information Update: 07 Nov 2025
At a glance
- Originator Solstice Pharmaceuticals
- Class Contrast media; Lipids
- Mechanism of Action Ultrasonography enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Kidney disorders
Most Recent Events
- 26 Sep 2025 HarMono-T microbubble - Solstice Pharmaceuticals is available for licensing as of 26 Sep 2025. https://solsticepharma.com/
- 12 Aug 2025 Preclinical trials in Kidney disorders in Germany (IV) prior to April 2025
- 12 Aug 2025 Solstice Pharmaceuticals withdraws a phase I/II trial prior to enrolment (In volunteers, Diagnosis) in Germany (IV, Infusion) (CTIS2024-514924-17-00)